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Anti-proliferative  effects  of calcium  in the  colon  are mediated,  at least  in part,  via the  calcium-sensing
receptor  (CaSR),  a vitamin  D  target  gene.  The  expression  of  CaSR  decreases  during  colorectal  tumor
progression  and  the mechanisms  regulating  its expression  are  poorly  understood.  The  CaSR  promoter
harbors  vitamin  D elements  responsive  to 1,25-dihydroxyvitamin  D3 (1,25D3) and  NF-B,  STAT,  and  SP1
binding  sites  accounting  for responsiveness  to proinﬂammatory  cytokines.  Therefore,  in the  current  study
we investigated  the  impact  of 1,25D3, tumor  necrosis  factor  alpha  (TNF),  and  interleukin  (IL)-6  on CaSRalcium-sensing receptor
olon cancer
umor necrosis factor alpha
nterleukin-6
expression  in a  differentiated  (Caco2/AQ)  and  in  a moderately  differentiated  (Coga1A)  colon  cancer  cell
line. 1,25D3 induced  CaSR  expression  in both  cell  lines.  Treatment  with  TNF  was  accompanied  by  a  134-
fold  induction  of  CaSR  in Coga1A  (p  <  0.01).  In  Caco2/AQ  cells  the  expression  of CaSR  was  upregulated
also by  IL-6  (3.5-fold).  Our  data  demonstrated  transcriptional  and  translational  activation  of the  CaSR  by,25-dihydroxyvitamin D3
nﬂammation
1,25D3,  TNF,  and  IL-6  in a time-  and  cell  line-dependent  manner.
This  article  is  part  of a  Special  Issue  entitled  ‘16th  Vitamin  D  Workshop’.
© 2013  The  Authors.  Published  by  Elsevier  Ltd.  All  rights  reserved.
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Epidemiological studies demonstrate an inverse correlation
between calcium and vitamin D intake and risk of tumor
development [1,2]. The calcium-sensing receptor (CaSR) is a puta-
tive tumor suppressor gene in the colon, which partially mediates
the anti-proliferative and pro-differentiating actions of calcium in
colonocytes (for review, see [3,4]). However, in colon cancer anti-
proliferative effects of Ca2+ are lost [5,6], and this could be due to
loss of CaSR expression during colorectal tumorigenesis [7]. Very
reserved.
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Fig. 1. Schematic illustration of the CaSR promoter region including exon 1A and exon 1B. Position of binding sites for regulatory elements is shown (signal transducer and
a or kappa B (NF-B), speciﬁcity protein 1 (SP1)), which are critical for 1,25D3, TNF, and
I S) 1 and 2 according to [12] were taken as point of reference for positioning the indicated
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L-6  responsiveness, as well as the CAAT and TATA boxes. Transcription start sites (TS
inding sites in the corresponding promoters.
ittle is known about the factors that regulate the expression of
aSR in the colon. The CaSR gene contains 6 coding exons and
wo 5′-untranslated exons (exons 1A and 1B), which are under
he control of promoter 1 and 2, respectively, yielding alternative
ranscripts but coding for the same protein [8,9]. Several studies
erformed in rat parathyroid, thyroid, and kidney have mapped
inding sites of numerous transcription factors, including NF-B,
TAT, SP1, and vitamin D response elements in both CaSR promo-
ers (Fig. 1) [9–12]. Currently, there is limited knowledge regarding
he role of 1,25D3 and of the proinﬂammatory cytokines TNF and
L-6 on CaSR expression in the colon. Therefore, in the present
tudy, we studied the impact of 1,25D3, TNF, and IL-6 on trans-
riptional and translational regulation of CaSR in two  colon cancer
ell lines with different proliferation and differentiation properties,
imicking different tumor stages.
. Materials and methods
.1. Cell culture
Caco2/AQ cells are a subclone of the Caco-2 cell line [13]. These
arry a truncated APC and a missense mutation of -catenin, and are
ble to differentiate spontaneously in culture. In the current study
e used highly differentiated, 2 weeks post-conﬂuent Caco2/AQ
ells. Coga1A is a cell line derived from a moderately differen-
iated (G2) colon tumor [14]. These cells are heterozygous for
runcated APC, without any known -catenin mutations [15]. Con-
uent Caco2/AQ and Coga1A cells were treated for 6, 12, 24, and
8 h either with 10 nM 1,25D3, 50 ng/mL TNF (Sigma Aldrich,
SA), 100 ng/mL IL-6 (Immunotools, Germany), or the combination
f these compounds. Vehicle treated cells were used as controls.
.2. RNA isolation, reverse transcription, and real time qRT-PCR
RNA isolation and reverse transcription were performed as
escribed previously [16]. Real time qRT-PCR analyses were
erformed in StepOne Plus system using POWER SYBR GREEN
astermix following the manufacturer’s recommendations (Life
echnologies, USA). Data were normalized to the expression of
he reference genes: 2M or RPLP0 [17,18], and set relative to
he calibrator (Clontech, USA) to calculate the CT value. Primer
equences for CaSR were: 5′-AGCCCAGATGCAAGCAGAAGG-3′ for-
ard, 5′-TCTGGTGCGTAGAATTCCTGTGG-3′ reverse.
.3. Immunoﬂuorescent staining of colon cancer cells
Cells were grown on sterile glass cover slips. After treatments
ells were ﬁxed with 3.7% paraformaldehyde in PBS, permeabil-
zed with 0.2% Triton-X (Sigma Aldrich, USA) for 20 min, and
locked with 5% goat serum (Jackson ImmunoResearch, USA). Cells
ere incubated either with rabbit polyclonal anti-CaSR antibody
1:100, Anaspec, USA) or mouse monoclonal anti-CaSR antibody
1:200, Abcam, UK) for 1 h at room temperature. As negativeFig. 2. Transcriptional regulation of CaSR by 1,25D3 in colon cancer cell lines.
Caco2/AQ and Coga1A cells were treated with 10 nM 1,25D3 for the indicated time
points. Bars represent mean ± SEM of 2-3 independent experiments.
control we used rabbit or mouse IgG, respectively (Abcam, UK and
Life Technologies, USA). As secondary antibody we used Dylight
labeled 549 goat-anti-rabbit or Alexa Fluor 647 goat-anti-mouse
IgG (1:500, Vector Laboratories and Life Technologies, USA). Nuclei
were stained with DAPI (Roche, Switzerland). Images were acquired
using TissueFAXS 2.04 (TissueGnostics, Austria).
2.4. Statistical analysis
All statistical analyses were performed with SPSS version 18 and
graphs were drawn with GraphPad Prism version 5. In case of non-
normal distribution, data were log transformed to achieve normal
distribution and then subjected to one way ANOVA, followed by
Tukey’s multiple comparisons posttest. p-values smaller than 0.05
were regarded as statistically signiﬁcant.
3. Results
3.1. Impact of 1,25D3 on CaSR expression
To study the role of vitamin D response elements on trans-
criptional regulation of CaSR expression we treated Caco2/AQ and
Coga1A cells with 1,25D3 for 6, 12, 24, and 48 h. In differentiated
Caco2/AQ cells treatment with 1,25D3 caused 2.4-fold induction
of CaSR expression after 6 h. The maximal effect of 1,25D3 on
CaSR transcriptional activation in these cells was observed at 24 h
(7.6-fold; Figs. 2A and 3C). In the less differentiated cells Coga1A
1,25D3-induced CaSR transcription was  2.9-fold after 12 h and 4.2-
fold after 24 h compared with the control group (Fig. 2B). 1,25D3
increased CaSR translation as well. Immunoﬂuorescence staining
demonstrated upregulation of the CaSR protein in Caco2/AQ after
24 h and Coga1A after 48 h (Fig. 3C and D).
3.2. Impact of TNF  ˛ and IL-6 on CaSR expressionWe treated Caco2/AQ and Coga1A cells with TNF and IL-6 for
6, 12, 24, and 48 h. In Caco2/AQ treatment with the proinﬂam-
matory cytokine TNF caused only modest upregulation of CaSR
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Fig. 3. Effect of 1,25D , TNF, and IL-6 on CaSR expression. (A and B) mRNA expression of Caco2/AQ and Coga1A cells assessed by real time qRT-PCR. Data were log
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f  2-3 independent experiments, asterisks above bars indicate statistically signiﬁc
taining of the CaSR protein (red) and nuclear staining (blue). Scale bar was 50 m.
xpression. Treatment with IL-6 was accompanied by a 3.5-fold
nduction after 6 h compared with control. Combined treatment
ith TNF and IL-6 induced CaSR mRNA expression in Caco2/AQ
0.3-fold (p < 0.05) after 24 h and 10.2-fold (p < 0.05) after 48 h.
owever, the combination of all three compounds either had no
ffect or reduced CaSR expression (Fig. 3A).
In Coga1A cells, treatment with TNF induced CaSR robustly,
specially at 48 h (134-fold, p < 0.01). Treatment with IL-6 caused
nly marginal increases in CaSR mRNA expression. Furthermore,
e observed upregulation of CaSR expression in the groups treated
ith TNF/IL-6 (68.5-fold) and TNF/1,25D3 (121.2-fold, p < 0.05)
t 48 h. Similar results were observed in the groups that were
reated with TNF/IL-6/1,25D3 at 6 and 48 h (18.8-fold, p < 0.05 and
7.7-fold, p < 0.05; Fig. 3B).
To address the question whether alterations on CaSR mRNA
xpression were translated into protein, we performed immuno-
uorescence staining. Fig. 3C and D demonstrates the upregulation
f the CaSR protein upon treatments with the proinﬂammatory
ytokines using the rabbit polyclonal anti-CaSR antibody. Proteinected with Tukey’s posttest for multiple comparisons. Bars represent mean ± SEM
anges compared with control. *p < 0.05, **p < 0.01. (C and D) Immunoﬂuorescence
expression data were conﬁrmed using the mouse monoclonal anti-
CaSR antibody (data not shown). Both antibodies gave the same
results.
4. Discussion
Recent studies have demonstrated that murine CaSR activates
the NLPR3 inﬂammasome, which in turn induces maturation and
release of the inﬂammatory cytokine interleukin 1, amplifying the
inﬂammatory signal [19,20]. Inversely, mice double knockout for
CaSR−/−/PTH−/− had increased inﬂammatory response after admin-
istration of dextran sodium sulfate compared with control mice
expressing the receptor [21]. This suggests an important role for
the CaSR in inﬂammation. Therefore, it is essential to understand
how the expression of the CaSR is modulated in the colon.It has been demonstrated previously that activation of VDREs
by 1,25D3 and translocation of NF-B to the nucleus after the
treatment with interleukin 1 led to induction of CaSR expression
in rat parathyroid, thyroid, and kidneys [9,10]. Furthermore, IL-6
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njection in rats caused induction of CaSR transcription via Stat1/3
esponse elements in promoter 1 and Sp1/3 sites in promoter 2 [11],
ut not much is known about the regulation of CaSR expression in
he colon.
Our study is the ﬁrst to show that in colonocytes inﬂammatory
ytokines are able to upregulate CaSR expression, and that this
ffect is time- and cell line-speciﬁc. In the present study, we  inves-
igated the role of 1,25D3, TNF, and IL-6 on the transcriptional and
ranslational activation of the CaSR in two cell lines representing
 highly differentiated and a moderately differentiated colorectal
umor.
1,25D3 is known for its anti-proliferative, pro-differentiating
ffects (for review, see [22]), and its involvement in regulating epi-
enetic mechanisms [23]. Inducing expression of CaSR, a putative
umor suppressor in the colon, might be one of the tumor preven-
ive mechanisms of 1,25D3. In the differentiated Caco2/AQ cells
,25D3 had more pronounced impact in inducing the expression
f CaSR than in the less differentiated Coga1A cells. In Caco2/AQ
ells treatment with 1,25D3 reduced the expression of several pro-
iferation markers also. This was much less evident in the Coga1A
ells (data not shown), although the level of the vitamin D receptor
s similar [15].
In Caco2/AQ cells, both TNF and IL-6 increased CaSR expres-
ion to a lesser extent than 1,25D3. In combination, however, they
aused a strong upregulation at 6 h, which was lost at 12 h; at 24 h
he effect became additive and the CaSR level remained high also
fter 48 h. We  hypothesized that two different mechanisms were
esponsible: ﬁrst, direct upregulation of CaSR expression due to a
ransient activation of CaSR promoters by NF-B upon treatment
ith TNF and Stat1/3 and Sp1/3 elements by IL-6. This was  fol-
owed by a second induction of transcription that seems to be
ndirect. Some (still unknown) factors induced by TNF and IL-6
ight be needed for this more stable induction of CaSR expression.
nexpectedly, 1,25D3 counteracted this additive effect, suggesting
he existence of intricate feedback systems.
In Coga1A cells, the CaSR was more sensitive to the proin-
ammatory cytokine TNF, which was the main driver of CaSR
xpression in these cells. The low effectiveness of IL-6 in upregulat-
ng CaSR expression could be due to lower levels of the IL-6 receptor
omplex (both the IL-6 binding  chain and the signal transducing
nit gp130) in Coga1A cells compared with Caco2/AQ [24]. Inter-
stingly, in these cells the CaSR protein levels remained enhanced
n all combined treatments. The robust increase of CaSR expression
y TNF treatment in Coga1A cells could be regarded as a defense
echanism against inﬂammation. Such protective mechanism was
hown in murine macrophages, where lipopolysaccharide-induced
NF release upregulated CaSR expression leading to inhibition of
NF synthesis, in a negative feedback manner [25].
In conclusion, our results demonstrate for the ﬁrst time that in
olon cancer cells not only 1,25D3, but also the proinﬂammatory
ytokines TNF and IL-6 were able to induce the expression of
aSR. How this observation can be translated in vivo and used
or the treatment of inﬂammation in the gut, still needs to be
xplored.
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